Crescendo is an England-based clinical-stage immuno-oncology company that researches and develops T-cell human body therapeutics for the treatment of cancer... Read more
Crescendo is an England-based clinical-stage immuno-oncology company that researches and develops T-cell human body therapeutics for the treatment of cancer... Read more
News
Apr 10, 2024
Yahoo
Crescendo Biologics: Crescendo Biologics presents preclinical data on lead clinical candidate CB307 and unveils its first '2 in 1' immune cell engager CB699 at AACR 2024
Mar 06, 2024
GlobalNewswire
Press Release: Crescendo Biologics : Crescendo Biologics to present at the 2024 AACR Annual Meeting
Dec 06, 2023
MarketScreener
Crescendo Biologics: IP : Crescendo Biologics - Announces first U.S. patients dosed in expanded Phase 1b clinical trial of CB307 for patients with mCRPC
Aug 03, 2023
Pulse2.0
Crescendo Biologics: Crescendo Biologics: $32 Million Raised To Develop Targeted T Cell Enhancing Therapeutics
Jul 25, 2023
Contract Pharma
Crescendo Biologics: Crescendo Biologics Secures $32M to Expand CB307 Trial
Apr 15, 2023
Pharmabiz
Crescendo: ANGLE inks contract with Crescendo for use of CTC biomarkers in clinical trials
Apr 14, 2023
Contract Pharma
Crescendo: Angle PLC, Crescendo Biologics Ink Clinical Services Contract
Jan 31, 2023
European Biotechnology
Crescendo: Ultra-processed foods increase risk for cancer
Jan 11, 2022
BioPharma-Reporter
Crescendo: BioNTech and Crescendo Biologics team up to develop multi-specific precision immunotherapies
Jan 10, 2022
Markets Insider
Crescendo: BioNTech, Crescendo Biologics Ink 3-year Deal For Multi-target Discovery - Quick Facts
Crescendo Biologics Competitors
1
2
3
4
5
6
7
8
9
10